First patients test new 'Immune Redirecting' drug for Tough-to-Treat prostate cancer
NCT ID NCT04397276
Summary
This early-stage study tested a new drug, JNJ-70218902, in men with advanced prostate cancer that had stopped responding to standard treatments. The main goals were to find a safe dose and see how the body handles the drug. The drug works by guiding the patient's own immune cells to find and attack the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BC Cancer Agency - Vancouver BC
Vancouver, British Columbia, V5Z 4E6, Canada
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Hosp Univ Hm Sanchinarro
Madrid, 28050, Spain
-
Hosp Univ Vall D Hebron
Barcelona, 08035, Spain
-
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
Rambam Medical Center
Haifa, 31096, Israel
-
Sourasky Medical Center
Tel Aviv, 64239, Israel
Conditions
Explore the condition pages connected to this study.